Tarsons Products Ltd

NSE:TARSONS

Earnings Call Transcript 2025-Q2

[Operator]

Ladies and gentlemen, good day, and welcome to Tarsons Products Limited Q2 FY '25 Earnings Conference Call hosted by Avendus Spark. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. [Operator Instructions] Please note that this conference is being recorded.

I now hand the conference over to Mr. Sundar from Avendus Spark. Thank you, and over to you, sir.

[Gnanasundaram Saminathan, analyst]

Thank you, Del. Festive greetings to one and all from Avendus Spark. On behalf of Avendus Spark, we welcome you to the 2Q FY '25 Conference Call of Tarsons Products Limited. From the management side, we have Mr. Aryan Sehgal, Promoter and Whole-Time Director; and Mr. Santosh Agarwal, CFO, on the call.

I now hand over the call to the management for the opening remarks and for the subsequent question-and-answer session. Thank you, and over to you, sir.

[Rohan Sehgal, executive]

Good afternoon, everyone, and a very warm welcome to our Q2 and H1 Earnings Conference Call. Along with me today, I'm joined by Mr. Santosh Agarwal, Chief Financial Officer and Compliance Officer for Tarsons; and SGA, our investor relations advisers. We have uploaded our quarterly investor presentation on the stock exchanges and company's website. I hope you all have had an opportunity to go through the same.

The domestic and international market for plastic labware remains subdued for the last few quarters. However, our recent interaction with customers, we are seeing an indication of industry resurgence along with the rise in order inquiries in both the international as well as the domestic markets.

The industry has faced several challenges over the past 2 years but we believe these are temporary. With our decades of experience, we have encountered similar situations in the past and have successfully overcome them. We believe that the sector now seems to be on a recovery mode as evidenced by the rising demand and our growing clientele. We see the current situation as a chance to expand and fortify our footprint in both the domestic and foreign market.

We are in a strong position to gain traction by utilizing our cost-effective manufacturing processes and high-quality product line offering. We plan to progressively grow our market share on the back of our products' dependability from the [indiscernible] with the long-term objective of capitalizing on the growing market opportunity.

In the interim, we have been actively participating in several international and domestic exhibitions to capture new customers and target new markets. These platforms have given us the opportunity to showcase our broad range of products, its durability, variety and exceptional quality to prospective customers.

One of the most important aspects of our long-term growth strategy is our involvement in these events. We hope to draw attention from a wide variety of sectors and regions by presenting our products on a global scale. Initial engagement along with several fresh possibilities of people inquiries have been received. However, order conversion may take some time.

We think we are headed in the right direction and should be able to increase our revenues over time from these new clients and once our new facility gets fully commissioned. In addition to reaffirming our dedication to growing our worldwide presence the strategic approach guarantees that we will be in a strong position to gain a greater market share as we continue to launch new products and improve our current lineup.

By increasing our capacity and capabilities with our planned plant in Panchla, we have also made a significant process. This facility has been constructed with the intention of meeting the expanding needs of plastic labware industry over the next 3 to 5 years. To expand our offerings and expand our addressable market, this new facility will not only boost the manufacturing capacity of our current product line, but we also intend to introduce new products like the cell culture line, to enhance our total addressable market.

Our plant in Panchla has started trial production for various product lines. There is a slight delay in the production due to the damage of the machinery modules during the sea transit in the previous quarter. However, we anticipate that the facility will be fully operational in the next few months, enabling us to generate revenues in FY '26 and beyond.

There is a high degree of operating leverage in our business and as revenues will increase, there will be faster adoption of the fixed costs, enhancing the margins moving forward. This new Panchla plant will increase our capacity and will also help us to participate in large global brands. From this Panchla plant, our target will be to serve both the domestic and the international market as we are already a well-known brand with firm client connections cultivated over many years.

This new facility will be able to provide a wide range of products for the plastic labware industry in India and globally, establishing Tarsons as a comprehensive and one-stop shop or plastic labware solutions, supporting us in gaining a large portion of new and existing businesses.

Regarding our Q2 performance, we are happy to report that our stand-alone revenues stood at INR 80 crores, up from INR 66 crores in Q2 FY '24, reflecting a growth of around 21%. We have been able to increase our top line indicating increase in the market share in the industry among our customers. This also indicates a gradual demand recovery and allows us to believe a positive recovery is around the corner and reaffirms our optimism for future growth and profitability.

In FY '24, we acquired Nerbe, a German distributor of plastic labware to establish a local presence and expand our footprint in strategic meetings. Currently serving a number of clients in different areas, Nerbe will provide Tarsons a good strategic entry point in the years to come. To promote our new products and increase Tarsons product line across Europe, we want to take advantage of Nerbe's capabilities. We have no doubt that this approach will boost Tarsons sales, attract new clients and boost our profitability.

On consolidated levels, revenue for Q2 stood at INR 99 crores, and for the first half of the year stood at INR 184 crores.

With this, I would like to hand over the call to Mr. Santosh Agarwal, CFO for Tarsons, for his comments on the financial highlights.

[Santosh Agarwal, executive]

Good afternoon, everyone, and a very warm welcome to our Q2 and H1 FY '25 earnings calls. On a quarterly basis, the stand-alone revenue from operation for Q2 FY '25 stood at INR 80 crores, which has increased as compared to INR 66 crores in Q2 FY '24 at a growth of 21%. Our consolidated revenue from operations for Q2 FY '25 stood at INR 99 crores, revenue from Nerbe for Q2 FY '25 is INR 19 crores, which has been consolidated from 1st of January 2024. For Q2 FY '25, on a consolidated basis, the revenue from overseas stood at INR 47 crores and domestic INR 52 crore.

When we talk about the EBITDA, our stand-alone adjusted EBITDA for Q2 FY '25 stood at INR 49.8 crores as against INR 35.4 crores in Q2 FY '24. The stand-alone and adjusted EBITDA margin for Q2 FY '25 stood at 37.2%. The consolidated adjusted EBITDA margin for Q2 FY '25 stood at 31.9%. Margins were partially impacted due to certain regions like -- and additional provisioning of INR 6.3 crores has been made in Q2 FY '25 on the account of machine models damaged during transit. We are replacing the same instead of repairing the same in consultation with the overseas vendor. We have submitted the insurance claim for the same.

And the second reason is a change in product mix and the last reason is a lower EBITDA margin on account of Nerbe, which is a trading entity.

When we talk about the PAT, stand-alone profit after tax for Q2 FY' 25 stood at INR 12.9 crores with PAT margin of 16.1% and consolidated profit after tax for Q2 FY '25 was INR 10.3 crores with a PAT margin of 10.4%.

When we are talking about the half-yearly numbers, the stand-alone revenue from operation for H1 FY '25, stood at INR 145 crores, which has increased as compared to INR 129 crores in H1 FY '24 at a growth of around 12.5%. Our consolidated revenue from operations for H1 FY '25 stood at INR 184 crores, revenue from Nerbe for H1 FY '25 INR 39 crores, which has been consolidated from 1st January 2024. For H1 FY '25 on a consolidated basis, the revenue from overseas stood at INR 89 crores and domestic at INR 95 crores.

At an EBITDA level, our stand-alone adjusted EBITDA for H1 FY '25, stood at INR 49.9 crores as against INR 49.5 crores in H1 FY '24. The stand-alone adjusted EBITDA margin for H1 FY '25 stood at 34.4%. The consolidated adjusted EBITDA margin for H1 FY '25 stood at 29%, margins were partially impacted due to lower EBITDA margin on account of Nerbe, which is a trading entity.

At a PAT level, the stand-alone profit after tax for H1 FY '25, stood at INR 19.4 crores with a PAT margin of 13.4%, and consolidated profit after tax for H1 FY '25 was INR 14.3 crores with a PAT margin of 7.8%. The consolidated net debt as of 30 September stands at INR 285 crores.

Let me talk about the Nerbe financial. The company has clocked quarterly revenue of around INR 19 crores and the half-year revenue of INR 39 crores. In Q2 FY '25, Nerbe reported PAT of INR 36 lakhs and in H1 FY '25, Nerbe reported a PBT of INR 1.07 crores.

With this, I would like to open the floor for Q&A.

[Operator]

[Operator Instructions] The first question is from the line of Jaiveer Shekhawat from AMBIT Capital.

[Jaiveer Shekhawat, analyst]

Team, congratulations on encouraging recovery in this quarter. So I think my first question is just to understand that better. So it's been almost 12, 13 quarters wherein you had either reported flat or sort of decline in revenues. This quarter, there has been a very increasing pickup in your stand-alone business. So what's leading to that, if you can call out which end user segments are really driving this demand increase? And also whether this has sort of sustained in the third quarter as well?

[Rohan Sehgal, executive]

So I think the overall industry seems to be in a better position at this point of time. Internationally, we see a lot of demand recovery coming from the United States and Europe, which are primarily our major markets internationally. So there were a lot of inflationary pressures over the last few quarters, along with overstocking and less demand in the U.S. I think a lot of demand has started to pick up in the U.S. and Europe was less impacted as compared to the U.S., but things seem better in the U.S. as well.

Similarly, in India, I think our major customer base of research, which is government, semi-government, then there is the biopharma and the pharma group, which includes the CROs, the pharmaceutical companies, the biopharma companies, the educational institutions, and then the diagnostic and the hospital segment, I think most of the segments are consistent, doing well. I still feel that the private customers in the biopharma and the contract research organizations continue to outperform the other sectors. But all the 4 major customer groups in India seem to be relatively stable at pre-COVID levels and positioned to grow at industry levels from here onwards.

[Jaiveer Shekhawat, analyst]

Sure. Second, you also called out additional provisioning on your machinery, which got damaged in transit. So is there any further provisioning that is left with respect to the machine?

[Santosh Agarwal, executive]

So Jaiveer, I would like to take this question. So we have initially estimated a INR 3 crore of provision in the first quarter. With all that, we will do the repair. But later on in the second quarter, we came to know that repair is not viable. That's why we are going for the replacement of the complete model. That's the reason this total provision of [indiscernible] has been done and insurance claim already been submitted, and we are waiting for the claim approval. But we don't think that there will be any additional provision for that.

[Jaiveer Shekhawat, analyst]

Sure. That's very helpful. Thirdly, on your Panchla facility, you've guided that possibly by end of this year, you will be able to fully operationalize the facility. So I mean, without the capacity, I mean, what kind of a peak revenue potential can you achieve? And then with that facility operations, I think what would be the big revenue potential for Tarsons at that moment?

[Rohan Sehgal, executive]

So at this point of time, I believe that with the exception of these replacement modules and certain other machines, most other machines could be operational by this financial year end, which is about 4 months away. But the products which are -- which we are replacing, which were damaged and certain cell culture lines could be installed and commissioned in Q1 of the coming year. But without Panchla generating any revenue, I believe that the company has a potential revenue of about INR 350 crores to INR 360 crores. And post-Panchla operation, it's equal to almost our company size, so another INR 350 crores to INR 360 crores.

[Jaiveer Shekhawat, analyst]

Sure. And we have not really seen any material decline in your inventories and plus even your borrowings have sort of increased. So what's the plan of action there to sort of reduce the inventories and then the borrowings as well?

[Santosh Agarwal, executive]

If you see our inventory level in the month of March and in the month -- in the quarter of June, that was around INR 110 crores. And if you see our current inventory level, there is also at sub INR 115 crores. But if you compare just inventory with our sales that has been -- while better optimized in the current quarter. So in the last quarter, if we have done INR 62 core of revenue, in this quarter, we have done about INR 280 crores of revenue, but the inventory level are almost same.

[Jaiveer Shekhawat, analyst]

Sure. And any comments on your borrowing levels as well because that continues to sort of balloon up?

[Santosh Agarwal, executive]

Regarding the borrowing, we believe that volume level will stay at the same level for a certain point of time, maybe for 2 to 3 quarters. And after that, we will see a decline on that. But we don't see any further increase in the current level in the number.

[Jaiveer Shekhawat, analyst]

Sure. And my last question is possibly on your Nerbe entity as well because if you see you consol level margins, I mean these are still hovering in the mid-20s range. So I mean what would be your strategy to sort of turn around margins for your Nerbe entity? And then I mean, where do you see the consol margins sort of heading in FY '26 and '27?

[Rohan Sehgal, executive]

So I'm not looking at it on a consol level for now. I think our entire strategy over the next 2 to 3 years would be to be able to align all the revenue synergies, what Tarsons has with Nerbe. And Nerbe is a different entity, which runs in Germany. It's a part of the Tarsons Group, but there are certain cost structure, certain obligations and it would probably not be possible for Nerbe to have similar revenues as that to Tarsons because if we would be having products delivered from Tarsons, Tarsons earning its margin, for Nerbe to earn similar margins, then go to the end customer, I don't think the market has an appetite for such kind of pricing. So no, they would always have distributor-like margins, which should be significantly lower in manufacturing at margins, but the whole idea would be to be able to scale up and synergize to the peak potential in the next 2 to 3 years, whatever Tarsons can do with Nerbe.

[Operator]

[Operator Instructions] The next question is from the line of Abdulkader Puranwala from ICICI Securities.

[Abdulkader Puranwala, analyst]

So first question is again on Nerbe. So I mean, have you started shipments for Nerbe from the India manufacturing plant or this continues to be sourced from overseas only?

[Rohan Sehgal, executive]

It continues to be sourced from outside Tarsons at this point of time.

[Abdulkader Puranwala, analyst]

Okay. And any plans to bring that to your India facility?

[Rohan Sehgal, executive]

See, at this point of time, we are looking to stabilize the plant what we are building. I've spoken in the last question, this plant would be the size of the entire company. So we are probably -- as this plant is doubling the capacity of our company. So we were supposed to do the integration around this time around, but slight delays in the Panchla facility have caused this delay. So once we have our capacities and our product lines in place, we would start the integration process.

[Abdulkader Puranwala, analyst]

Understood. And second is on Panchla. So in terms of your commercialization, so what would be the impact of this machinery? What has got impacted in terms of your commercialization? Do you see that this want to be critical -- of a critical mass for your early commercialization for a new set of products and that gets delayed? And second is, by when do you expect the insurance claims to get reimbursed for the losses that you have incurred?

[Rohan Sehgal, executive]

So for the first question, there's a delay in time and we placed the replacement orders for the modules which were damaged. And we expect the modules to be commercialized in the first quarter of FY '26, the damaged modules to be replaced, delivered to us and commercialized. We've got the right people and the right team and the best minds to handle our insurance case with the insurance company, and that's all I can say for now. I don't know when this would end and when it would come in our favor. But what I understand from the experts who are dealing with our case, that our case is strong, and we should be -- we have -- it's a clear case of products being damaged during transit for which there was an insurance.

[Abdulkader Puranwala, analyst]

Okay. Got it. And just a final one on the industry. So you talked about the industry showing somewhat [ weak, 5 or 6 ] months back. So I mean does that make us confident that this 20% growth, what we have showcased in the stand-alone business, that gets continued for the quarter? Or if we have to talk about FY '26, what is the kind of visibility do we have there?

[Rohan Sehgal, executive]

So we won't be giving any forward-looking statements on what sort of growth we expect. We're not giving any guidance here. But Tarsons has grown sustainably at 16% to 18% from the last 15 years up until we IPO-ed. Then we came through this phase of post-COVID overstock and slump in industry demand. So those were the 2 years in the last 17 years that we had not grown in that CAGR of 16% to 18%. So the industry is stable and smooth and so is our company, product and operations, I don't see that being repeated again.

[Abdulkader Puranwala, analyst]

Okay. Understood. And just a final one on the cell culture business what you have talked about earlier. So I mean, in terms of commercialization, what is the timeline there? And any customer addition or any outlook on the revenues for that particular segment would be helpful.

[Rohan Sehgal, executive]

So we have approximately 7 or 8 production lines coming in cell culture. The first production line is ending commercialization in our facility as we speak today. So it's been on -- just to give you an idea, the people who came down to commercialize this project, came down in the first week of September. And they would be closing this plant and successfully giving us the certificate and [ ending ] by this week. So it was an 8-week process -- with certain holidays of Durga Puja and Diwali in middle.

So similarly, with Line 1 [ done ], we have Line 2 and Line 3 already delivered to us and such commercializations would start in the coming weeks of November. So we have 7 total lines of cell culture, which will be installed, and we expect 3 or 3.5 lines to be done by this calendar year, which is 31st December, and the other ones in the preceding months after December and January to March.

[Operator]

[Operator Instructions] The next question is from the line of Vipin Goel from Mirabilis Invest.

[Unknown Analyst]

Sir, I had a question on the gross margins of the stand-alone entity. I also suppose in the initial remarks you related to the commentary where you said that there is a change in product mix, which led to lower margins. So can you comment on the gross margin for the stand-alone entity? Because at some -- about 2 years back or so, we are operating at about 80% gross margins, that has now come down to 70%. So what are [ we seeing today ]?

[Rohan Sehgal, executive]

So we are at 80% gross margins for 2 quarters, and that was during the COVID period when there was a sale of a lot of high-end onetime products, which were not repeated in PCR testing or RT-PCR testing. But historically, the company ran around gross margins of early 70s, mid-70s, and that's what I've always said we could maintain. However, change in product mix is launching of new products to offer promotional prices, to propel change for customers, a lot of inventory in the system and being able to offer competitive prices, to move product, all that leads to lower gross margins and I think we're in a very healthy position at this point of time in terms of our margin, and we would not hesitate if our margins move slightly up or slightly down as we scale up our business in the future.

[Unknown Analyst]

Got it. So 70% is a good go-ahead and long-term average that can be assumed for the for the current [indiscernible]?

[Rohan Sehgal, executive]

Since we don't have one product which decides our margins or 2 or 3 products, we're working on 3,000 SKUs, and we don't have any like top-selling or new products, where I think one SKU or 5 SKUs account for 50% or 60% of our business. So I don't have so much of visibility. I would say about 300 or 400 SKUs account for about 90% of my business or 80% of my business. So any change in those mixes, any change in market scenarios, any change in market conditions, that could be large RFPs or large global business [indiscernible]. So I would like to restrict myself saying 70% -- if our business grows at a very, very healthy rate, and that should become 67%, I would not hesitate. But if that should become 40% or 50%, I would probably have to think twice because there are other costs associated with the company.

[Unknown Analyst]

Got it. Got it. That's very helpful. And sir, one question on the Nerbe entity. So while I understand that you initially mentioned that the entity will always have a distributor margin. So what [indiscernible] to put that in -- put in a number to that. So what would that be? It's like 10% or 15% or what percentage number of margins would be?

[Rohan Sehgal, executive]

So I don't think the EBITDA levels to expect the European company, especially operating in Germany in the life science sector, to have more than 15% EBITDA margin. If you look at the leading companies in Europe, which include the manufacturing of certain consumables, which are similar to what Nerbe does business in, they would operate at around 18% to 20%. So being an entity, which primarily is a marketing agency for such products, I don't think beyond 15% -- in or around the 15% mark would be a reasonable estimation.

[Unknown Analyst]

Got it. Got it. sir, I mean -- I might be wrong here, but when I look at the press release, which was put out when we had acquired Nerbe, at some point and probably that was also a COVID-related factor. At some point, they were reporting some 20 double-digit margins, some 30 -- 20 -- 25 or 30 in that range. So was it like again, a COVID-related factor? Is there something has changed after we acquired the company and it has become a [ distributor ]?

[Rohan Sehgal, executive]

What really happened, the Nerbe revenue was around EUR 30 million back in COVID. And today, it's a fraction of that. So there was the testing in Germany and around Europe was at its peak, and Nerbe had a very, very efficient supply chain management and very, very efficient suppliers who have long-term agreements with. And they could utilize and leverage their network and their supply-chain capabilities to have product available when nobody had product available for critical testing of patients and that led to a huge surge in demand.

But Nerbe overall moving forward is a company which is more towards the life science industry, where we are present in, which is looking after researchers who are using the product to conduct research, conduct clinical trials or to conduct any sort of vaccine production and so on. But Nerbe's main business that generated those revenues were more towards [ insurance ] and medical, which is not its core business, which was swabs. And today, that is diverted back to the life science business. So it was a onetime opportunity, which is today lost, post-COVID.

[Santosh Agarwal, executive]

And just to add, if you talk about Nerbe result, in calendar year 2021, they reported EUR 30 million revenue, right? And at that point of time, the gross margin was about 50%. And when we are reporting about the EUR 4.2 million of revenue in H1, at this time also, the gross margin is about to [ 50% ]. So only thing which changed is the [ labeling ] because of the -- at that point of time, the EBITDA was about to be 35%. And now their EBITDA [indiscernible].

[Rohan Sehgal, executive]

I mean, also still nothing changed in the size of the company, but the revenues ballooned up because of the great COVID opportunity that they had.

[Unknown Analyst]

Got it. Got it. That's very helpful. Sir, just -- I mean, as I'm just trying to kind of form an opinion on the -- for instance, the demand scenario is improving, as you mentioned from [ Berkeley ] from U.K. and then U.S. is also kind of reviving. So how to basically think about, let's say, the growth between the international business and the domestic business? In terms of revival, what would be the pecking order? And then what quantum of growth can be -- I mean, we can assume for the 2 regions?

[Rohan Sehgal, executive]

I assume that overall, the business in the international or the overseas business, the growth will be faster just because of the sheer scale of the business outside India. And our lower base outside India plus with the acquisition of Nerbe, our ratio of revenues have been quite aligned, almost equal between international and domestic. And domestic, our base is much higher. Our market is -- we are one of the market leaders. So our position is much stronger. So I feel that we would have solid growth domestically as well. But the numbers or the percentage might look better internationally or overseas as compared to domestic in the future.

[Unknown Analyst]

That's helpful. I'll just put in last one, which is a bookkeeping question. Just the INR 6 crore and INR 3 crore expense that we incurred because of this equipment provision. So that's sitting in other expense?

[Santosh Agarwal, executive]

No, that is correct [indiscernible] residing in other expenses. Absolutely.

[Operator]

The next question is from the line of Jasdeep Walia from Clockvine Capital.

[Jasdeep Walia, analyst]

You had launched some cell culture products 5, 6 months back, I think PET bottles and some other products linked to which are ancillary products to cell culture production. What has been the progress there? And have you been able to get good marquee customers in India who started buying those products commercially from you on recurring basis?

[Rohan Sehgal, executive]

Yes, we have been able to win some customers in India and overseas who are buying these products on a trial basis. So now, you know, if they have a demand of 100, they give us a certain portion of orders to see whether we can deliver and we see that their products sustain because they use high-end cell culture media to store and ship through these PET bottles. And hence, at this point of time, they've tried our products, they liked it, things work out well for them, and so they decided placing giant orders.

[Jasdeep Walia, analyst]

So they started placing commercial orders now?

[Rohan Sehgal, executive]

Absolutely, yes.

[Jasdeep Walia, analyst]

Got it, sir. And how scalable is this product segment, sir? If you could just give us the size of the segment in India?

[Rohan Sehgal, executive]

I think the size of the segment in India would be approximately $6 million to $7 million, the whole market for PET bottles.

[Jasdeep Walia, analyst]

Got it. And this will be primarily catered by global brands?

[Rohan Sehgal, executive]

Primarily imported for now. There's 2 segments. One is PETG, one is PET. So there are a lot of companies in India which manufacture the PET bottles, PET is widely used and in various customer segments and various customer price points, but PETG is still continues to be a specialized product line for cell culture.

[Operator]

The next question is from the line of Suresh Pal from KRSP Capital Limited.

[Unknown Analyst]

Yes, am I audible?

[Rohan Sehgal, executive]

Yes.

[Unknown Analyst]

Sir, my question is what is the outlook for this financial year regarding our revenue and margin both stand-alone and consolidated basis? Since we have seen an uptick both quarter 1, quarter 2 in terms of margin. So if you can shed some light?

[Rohan Sehgal, executive]

So I don't have any guidance numbers but we were close the year at, but I think the momentum is on the upwards and we should have similar quarters as this current quarter and the remaining 2 quarters.

[Operator]

The next question is from the line of Jatin Chawla from RTL Investments.

[Jatin Chawla, analyst]

My first question is, when I look at your balance sheet, your property, plant and equipment number has gone from like INR 245 crores to INR 390 and we still have a CWIP of about INR 200 crores. So broadly from a INR 240 crore net fixed asset, we will go to almost like INR 600 crores. So with that, what is the kind of increase in depreciation should we expect? Should we expect the depreciation number to go like INR 70 crores, INR 75 crores going forward?

[Santosh Agarwal, executive]

No, I think in this year, our depreciation number, we believe that should be approx INR 45 crores to INR 55 crores -- in between INR 45 crores to INR 50 crores.

[Jatin Chawla, analyst]

No, I was talking about 2 years out once the entire CapEx is done?

[Santosh Agarwal, executive]

You're talking about the entire CapEx when it will be completed, correct?

[Jatin Chawla, analyst]

Yes, once all the CapEx is completed, what would be like a quarterly depreciation rate? I think right now, it is at INR 12 crores. Will it move to INR 17 crores, INR 18 crores or how do you see it moving forward?

[Santosh Agarwal, executive]

It can move. Only thing is that we are [indiscernible]. So the previous [ materials -- ] the depreciation on the previous machine will keep on reducing [ and will keep on further reducing ]. So it should not move beyond INR 70 crores but we need to see what category of the property and plant and equipments are there because different depreciation [ are here ].

[Jatin Chawla, analyst]

Understood. Understood. My second question was on the Panchla plant, what sort of costs are already reflected in the 2Q results? So once commercial production starts, will we see some operating leverage because there are some costs which are sitting in the 2Q results?

[Rohan Sehgal, executive]

So I think we will see operating leverage once we start scaling up. We will see a lot of operating leverage. At this point of time, we have nearly 40% -- 30% to 40% people already working on the floor because of trial runs. A lot of fixed costs in terms of electricity, maintenance and other things all being paid, but I think the immediate operating leverage may not be there, but as we scale up and start getting volumes from Panchla there would be significant operating leverage.

[Jatin Chawla, analyst]

Understood. And you said you will start integration with Nerbe, maybe once the Panchla plant has stabilized a bit, so let's say, 3, 4 quarters down the line. But over a 3-year period, what sort of product portfolio of Nerbe can you supply from Tarsons? So let's say, they are doing broadly INR 100 crores a year, what is it that Tarsons can potentially supply in terms of product line?

[Rohan Sehgal, executive]

I think half the portfolio, we should be able to manage in 2- to 3-year period.

[Jatin Chawla, analyst]

Half the portfolio. Okay. Got it. Got it. And you said the inquiries have picked up significantly over the last quarter. And so what is the driver of this inquiry? Is it China Plus One or just the general recovery in demand? What are the real drivers of this recovery in inquiry that you're seeing?

[Rohan Sehgal, executive]

So I don't think China Plus One -- China Plus One was a big noise. We spoke about the China Plus One as well, but I didn't see a lot of action on the China Plus One so far, at least in our industry. There was a lot of talk, but not too much of action. I think it's just inventory levels turning to normal and industries, the end customers beginning to see an organic growth in their business, which is reflecting on organic growth in our business.

[Jatin Chawla, analyst]

Understood. Understood. And this 2Q result that you would given, you've said that, that is still in the context of a subdued industry demand. And with the inquiries that you've seen picking up, should we expect that the traction will improve further from where we are in 2Q?

[Rohan Sehgal, executive]

Very difficult to show when we reach the complete end, but I haven't seen subdued for this quarter for sure. I think the quarter was [ a strong ] quarter for us. And I [indiscernible].

[Operator]

Sorry to interrupt you, sir.

[Jatin Chawla, analyst]

I think your voice is not clear.

[Operator]

Sir, could you come [indiscernible].

[Rohan Sehgal, executive]

Is it clear now?

[Operator]

Yes, sir.

[Rohan Sehgal, executive]

[indiscernible]

[Jatin Chawla, analyst]

I can't hear you, sorry.

[Operator]

Still not clear, sir. Could you come a bit closer to handset?

[Rohan Sehgal, executive]

I'm right there. Is it audible?

[Operator]

Yes, sir, now it is better.

[Jatin Chawla, analyst]

Yes.

[Rohan Sehgal, executive]

Yes. So I think we've outperformed the industry in this quarter. There's no doubt about it, and gained market share, but especially in the domestic market. But I don't see that as the only reason or the main reason. I think the industry has strengthened and the demand levels have increased, and there's a positive uptick in the industry. So that has a big role to play in our numbers. So there is some credit to the company being able to gain market share. But mostly, it is an industry revival and the industry getting stronger.

[Operator]

Thank you. Ladies and gentlemen, that was the last question for today. I would now like to hand the conference over to the management for closing comments.

[Rohan Sehgal, executive]

Thank you all for joining us. I hope all your questions have been answered. Further, we will continue to provide the investment community with 2 quick updates on your company's developments. Please contact us or our investor relations advisers, [indiscernible] for further information or questions that you may have regarding Tarsons. Thank you again.

[Operator]

On behalf of Avendus Spark and Tarsons Products Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.